Free Trial

Bolt Biotherapeutics Q4 2024 Earnings Report

Bolt Biotherapeutics logo
$0.40 +0.02 (+4.70%)
As of 04:00 PM Eastern

Bolt Biotherapeutics EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.38
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Bolt Biotherapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
$0.79 million
Beat/Miss
Missed by -$780.00 thousand
YoY Revenue Growth
N/A

Bolt Biotherapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

Bolt Biotherapeutics Earnings Headlines

Leerink Partnrs Issues Positive Estimate for BOLT Earnings
Research Analysts Issue Forecasts for BOLT Q1 Earnings
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
What is HC Wainwright's Estimate for BOLT Q3 Earnings?
Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)
See More Bolt Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email.

About Bolt Biotherapeutics

Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

View Bolt Biotherapeutics Profile

More Earnings Resources from MarketBeat